IGI Laboratories (IG) to Release Earnings on Tuesday

Share on StockTwits

IGI Laboratories (NYSE:IG) will be releasing its earnings data on Tuesday, April 29th. Investors interested in registering for the company’s conference call can do so using this link.

IGI Laboratories (NYSE:IG) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.01) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.01 by $0.02. On average, analysts expect IGI Laboratories to post $0.03 EPS for the current fiscal year and $0.15 EPS for the next fiscal year.

Shares of IGI Laboratories (NYSE:IG) opened at 4.91 on Monday. IGI Laboratories has a 1-year low of $1.24 and a 1-year high of $6.14. The stock has a 50-day moving average of $5.03 and a 200-day moving average of $3.53. The company’s market cap is $230.9 million. IGI Laboratories also was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 279,070 shares, a growth of 79.4% from the March 31st total of 155,561 shares. Currently, 2.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 272,377 shares, the short-interest ratio is currently 1.0 days.

On a related note, analysts at Craig Hallum initiated coverage on shares of IGI Laboratories in a research note on Monday, April 21st. They set a “buy” rating and a $7.50 price target on the stock.

IGI Laboratories, Inc (NYSE:IG) develops, manufactures, fills and packs topical semi-solid and liquid products for cosmetic, cosmeceutical and pharmaceutical customers.

Receive News & Ratings for IGI Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGI Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Washington Real Estate Investment Trust Given Consensus Rating of “Hold” by Brokerages
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Qunar Cayman Islands Receives Consensus Rating of “Buy” from Analysts
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Neurocrine Biosciences Given Average Rating of “Buy” by Brokerages
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
Astoria Financial Corp Given Consensus Recommendation of “Hold” by Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
KBR Receives Average Recommendation of “Buy” from Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts
Vanguard Natural Resources Given Consensus Recommendation of “Hold” by Analysts


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 Mideast Time.